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ABSTRACT  
Background: Contrast medium-induced acute kidney injury (CI-AKI) is a cardiovascular 
complication after myocardial infarction treated with emergency percutaneous coronary 
intervention. The aim of this randomized, sham-controlled trial was to evaluate the impact of 
remote ischemic preconditioning (RIPC) on CI-AKI in patients with ST-elevation myocardial 
infarction who received emergency primary percutaneous coronary intervention. 
Methods and Results: Patients with a suspected ST-elevation myocardial infarction were 
randomly assigned at a 1:1 ratio to receive percutaneous coronary intervention either with 
(n = 63) or without (n = 62) RIPC (intermittent arm ischemia through three cycles of 5 min of 
inflation and 5 min of deflation of a blood pressure cuff). A total of 47 RIPC patients and 47 
control patients met all study criteria. The primary endpoint was the incidence of CI-AKI, which 
was defined as an increase in serum creatinine > 0.5 mg/dL or > 25% over the baseline value 
48–72 hours after administration of contrast medium. The incidence of CI-AKI was 10% (n = 5) 
in the RIPC group and 36% (n = 17) in the control group (p = 0.003). The odds ratio of CI-AKI 
in patients who received RIPC was 0.18 (95% confidence interval: 0.05–0.64; p = 0.008).  
Conclusions: In patients with ST-elevation myocardial infarction, RIPC before percutaneous 
coronary intervention reduced the incidence of CI-AKI.  
 
Keywords:  
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Percutaneous coronary intervention  
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1. Introduction 
 
 ST-elevation myocardial infarction (STEMI) is a leading cause of mortality and 
morbidity. The reduction of myocardial injury is the mainstay of therapy for STEMI and is best 
achieved by early reperfusion through emergency percutaneous coronary intervention (PCI) [1]. 
Patients receiving such treatment achieve infarct-related vessel patency and reperfusion, but risk 
sustaining clinically significant myocardial infarction, even when the procedure is done soon 
after symptom onset [2]. Cardiac complications after emergency PCI with STEMI, such as heart 
failure and cardiac rupture, are potentially lethal and lead to an impaired prognosis [3]. 
Additionally, contrast medium-induced acute kidney injury (CI-AKI), a cardiovascular 
complication after myocardial infarction, is a frequent complication of emergency PCI and is 
associated with an increased mortality rate and persistent renal dysfunction [4, 5]. 
 Remote ischemic preconditioning (RIPC) is the phenomenon in which transient 
nonlethal ischemia and reperfusion applied to one organ or tissue protects another organ or tissue 
from a subsequent episode of lethal ischemia and reperfusion [6]. A previous study showed that 
RIPC applied before PCI in patients with evolving STEMI was able to increase myocardial 
salvage [7]. Additionally, a recent study demonstrated that RIPC performed before administration 
of contrast medium prevented CI-AKI in moderate- to high-risk patients [8-10]. The role of RIPC 
in reducing CI-AKI in STEMI patients undergoing emergency PCI is not clear. In this 
prospective, randomized, sham-controlled pilot study, we evaluated the impact of RIPC on 
CI-AKI in patients with STEMI who received emergency primary PCI, and hypothesized that 
RIPC applied before PCI would reduce the incidence of CI-AKI in patients with STEMI. 
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2. Methods 
 This study was a prospective, single-blind, multicenter, randomized, sham-controlled 
parallel-group study conducted from 2012 to 2013 at Saiseikai Imabari Hospital, Ehime 
Prefectural Central Hospital, and Okayama University Hospital, in Japan. The study was 
approved by the ethics committees of all three hospitals, and written informed consent was 
obtained from all participants before beginning the protocol. This study was conducted according 
to the principles expressed in the Declaration of Helsinki. The study is registered at UMIN 
Clinical Trials Registry (UMIN000012578). 
 
2.1. Patient selection and randomization 
 
 Eligible patients were aged 20 years or older; presented with chest pain within 24 hours 
of onset; had ST-segment elevation of > 0.1 mV in two contiguous leads in the first 
electrocardiogram recorded on the scene; and were clinically assigned to receive primary PCI. 
Exclusion criteria were: left bundle branch block; previous coronary bypass surgery; severe heart 
failure requiring percutaneous cardiopulmonary support; and severe chronic kidney disease 
requiring dialysis or continuous hemodiafiltration. Patients who did not meet inclusion criteria 
were excluded either immediately on arrival at the hospital or when biochemical ischemic 
markers failed to confirm a diagnosis of myocardial infarction. Patients were excluded either 
when they fulfilled the definition of exclusion or when biochemical markers failed to confirm the 
diagnosis of myocardial infarction.  
 Patients were randomly assigned to receive standard primary PCI (control group) or 
standard primary PCI plus RIPC through intermittent upper-arm ischemia (RIPC group). Patients 
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were identified and randomized on arrival at any of the three participating hospitals soon after 
they were screened for eligibility. Randomization was stratified by sex and age (< 70 versus 
≥ 70 years). Patients were randomized 1:1 with computer-generated block randomization.  
 
2.2 Procedures 
 
 In the RIPC group, RIPC was initiated by medical staff at the hospital immediately after 
randomization and consisted of three cycles of ischemia/reperfusion of the upper arm achieved by 
5 min cuff inflation at 200 mmHg followed by 5 min of complete cuff deflation. The device used 
to perform RIPC was an automated continuous blood-pressure device (FB-270; Fukuda Denshi, 
Tokyo, Japan) that had been modified to perform the three cycles of inflation and deflation 
automatically. If there was insufficient time to complete three cycles of inflation and deflation 
before entering the catheter laboratory, the RIPC procedure continued before reperfusion was 
achieved. Control patients had an uninflated cuff placed on the right upper arm for 30 minutes. 
All patients received standard care according to established clinical practice guidelines. Before 
PCI, all patients were treated with 200 mg aspirin orally, 300 mg clopidogrel orally, and 
0.1 mg/kg/h continuous injection of nicorandil intravenously. After PCI, patients received a 
lifelong prescription for 100 mg aspirin and 75 mg clopidogrel daily. The hydration protocol 
involved continuous intravenous infusion of normal saline solution at a dose of 1 mL/kg of body 
weight per hour (reduced to 0.5 mL/kg of body weight per hour in patients with heart failure or 
fluid overload) beginning before PCI and continuing for 24 h after PCI. All patients received 
0.1 mg/kg/h continuous injection of nicorandil for at least 8 hours after primary PCI [11]. 
Coronary angiographic measurements were made immediately before revascularization using 
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standard techniques. At each hospital, all measurements were made by experienced individuals 
blinded to treatment assignment and clinical data. The choice of materials was left to the 
operators, with the exception of the radiographic contrast medium, which was a nonionic, 
low-osmolar solution in all cases.  
 
2.3. Primary and secondary endpoints 
  
 The prespecified primary endpoint was incidence of CI-AKI. CI-AKI was defined as an 
increase in serum creatinine > 0.5 mg/dL from the baseline value or a relative increase of > 25% 
of the baseline value 48–72 hours after injection of contrast medium (the maximum measured 
concentration of creatinine during this 24-hour period was used). Prespecified secondary 
endpoints were 1) maximum reduction in estimated glomerular filtration rate (eGFR), calculated, 
using the equation for modification of the diet in a renal study of Japanese individuals 
recommended by the Japanese Society of Nephrology, as: eGFR (mL · min
−1
 · 1.73 m
−2
) = 194 × 
[serum creatine]
−1.094
 × [age]
−0.287
 × [0.739 if female] in the 48 hours after PCI; maximum change 
in serum creatinine from baseline in the 48 hours after PCI; infarct size estimated by peak 
creatine kinase (CK); left ventricular ejection fraction 2 weeks after PCI; the incidence of 
sustained ventricular tachycardia or ventricular fibrillation within 24 hours after PCI; and the 
incidence of major adverse cardiac and cerebral events (MACCE) in the 30 days after PCI. These 
included hospital admissions with unstable angina or acute coronary syndrome, heart failure, 
cardiac rupture, cardiac death, stroke, and transient ischemic attack. Patients were followed by 
telephone on day 30 after PCI. Echocardiography was performed with the Vivid 7 cardiovascular 
ultrasound system (GE Healthcare, Milwaukee, WI, USA). LV ejection fraction was measured 
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according to the recommendations of the American Society of Echocardiography [12]. The 
personnel involved in data collection and handling were blinded to group assignments. Clinical 
endpoints were blindly adjudicated by two investigators.  
 
2.4. Statistical analysis 
 
 At the time of study design, limited clinical data were available for estimation of sample 
size [[10]]. The sample size was determined on the basis of the primary outcome, incidence of 
CI-AKI. We assumed that incidence of CI-AKI to be 30% and that RIPC would reduce the 
prevalence of CI-AKI by 10%; therefore, 94 patients were recruited into the study to enable such 
a reduction to be detected (power 90%, α = 0.05).  
 Intention-to-treat analysis of patients fulfilling inclusion criteria was performed. 
Continuous data are presented as mean ± SD and categorical data are presented as frequencies. 
Continuous variables were compared across groups (control, RIPC) using paired and unpaired 
Student’s t tests. Categorical variables were compared across groups using chi-square statistics 
and Fisher’s exact test. Pre-procedural estimated risk of CI-AKI was calculated using the Mehran 
Contrast-Induced Nephropathy (CIN) risk score [13]. A two-step analysis was used to identify the 
independent predictors of CI-AKI. First, a univariate analysis was used to identify the clinical, 
angiographic, or procedural risk factors for CI-AKI. Continuous variables were transformed to 
binary data according to the median value, with 1 indicating the presence of assumed risk factors 
and 0 otherwise. Second, univariate predictors with p < 0.05 were entered into a multivariate 
logistic regression model. The odds ratios (ORs) and 95% confidence intervals (CIs) from the 
final multivariate model are presented. Statistical significance was accepted for all p 
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values < 0.05.  
 
3. Results 
 
3.1. Study flow and patient characteristics 
 
 A flow diagram is shown in Fig. 1. One hundred twenty-five STEMI patients were 
randomized to receive RIPC before PCI (n = 63) or primary PCI alone (n = 62). Twenty-nine 
patients (15 in the RIPC group and 14 in the control group) were excluded because of no 
enzymatic evidence of infarction (n = 13), greater than 24-hour symptom-to-balloon time (n = 5), 
severe heart failure requiring percutaneous cardiopulmonary support (n = 8), receiving 
hemodialysis (n = 3), and withdrawal of informed consent (n = 2). Thus, 47 patients in the RIPC 
group and 47 patients in the control group met inclusion criteria and formed the study population 
for the analysis. 
 Baseline characteristics of all patients and those who met inclusion criteria are shown in 
Table 1. In patients with patients who met inclusion criteria, mean baseline serum creatinine 
value, eGFR, and Mehran CIN risk score were also not significantly different in the two groups 
(for RIPC and control, respectively: serum creatinine, 0.82 ± 0.21 versus 0.87 ± 0.44 mg/dL; 
eGFR, 73 ± 20 versus 79 ± 33 mL/min/1.73m
2
; Mehran CIN risk score, 7.8 ± 6.0 versus 
7.4 ± 5.7). The amount of contrast medium in patients with patients who met inclusion criteria 
was also similar in the two groups (177 ± 53 versus 199 ± 87 mL for RIPC and control, 
respectively; p = 0.08). The time from completion of RIPC to injection of contrast medium was 
16.9 ± 15.9 min. RIPC was successfully completed without complications in 47 patients. There 
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were no major PCI-related complications (death or urgent revascularization within the first 24 
hours) in either group. Angiographic parameters were similar between the two groups (Table 2). 
There were no significant differences in the infarct-related artery, Thrombolysis in Myocardial 
Infarction (TIMI) flow grade, symptom-to-balloon time, and intra-aortic balloon pump (IABP) 
support. Concomitant medications between completion of RIPC and the primary endpoint were 
similar between groups (Table 3).  
 
3.2. Primary endpoint 
 
 The incidence of CI-AKI after PCI was lower in the RIPC group (n = 5 patients, 10%) 
than in the control group (n = 17 patients, 36%; p = 0.003; Fig. 2A). Twenty-nine factors 
potentially associated with CI-AKI were analyzed by univariate analysis. Continuous variables 
were converted to binary data according to median value (Table 4). Two factors (age > 68 years 
and left anterior descending artery as the culprit artery) were positive predictors of CI-AKI, and 
four factors (male, current smoker, 50% or more ST-segment resolution and RIPC) were negative 
predictors of CI-AKI (Table 4). These six factors were entered into a .multivariate logistic 
regression model, which revealed that RIPC (OR: 0.40; 95% CI: 0.05 to 0.64; p = 0.008) and left 
anterior descending artery as culprit artery (OR: 3.50; 95% CI: 1.08 to 11.31; p = 0.03) were 
significant predictors of CI-AKI (Table 4). 
 
3.3. Secondary endpoints 
 
 The maximum decrease in eGFR was significantly greater in the control group than in 
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the RIPC group (10.2 ± 17.1 versus 0.17 ± 16.9 mL/min/1.73m
2
, respectively; p = 0.003; Fig. 2B). 
The maximum change in serum creatinine tended to be greater in the control group than in the 
RIPC group (0.15 ± 0.31 versus 0.03 ± 0.26 mg/dl; p = 0.06). Fig. 2C shows the serial change in 
serum creatinine. Serum creatinine in the control group was significantly higher than that in the 
RIPC group 48–72 hours after contrast injection (1.03 ± 0.61 versus 0.81 ± 0.21 mg/dL; 
p = 0.02).  
 Table 5 shows other secondary outcomes. Peak CK was significantly higher in the 
control group than in the RIPC group (3,653 ± 2,894 versus 2,648 ± 1,926 IU/L; p = 0.04). There 
was no difference in left ventricular ejection fraction 2 weeks after PCI between the control group 
and the RIPC group. The incidence of ventricular sustained tachycardia or ventricular fibrillation 
within 24 hours after PCI was significantly lower in the RIPC group (one patient, 2%) than that 
in the control group (seven patients, 14%; p = 0.01). The incidence of MACCE in the RIPC 
group (two patients, 4%) tended to be lower than that in the control group (seven patients, 14%), 
but the difference was not statistically significant (p = 0.07). The MACCE in the RIPC group 
were severe heart failure (n = 1) and ischemic stroke (n = 1), and in the control group were severe 
heart failure (n = 3), left ventricular perforation (n = 1), death due to refractory heart failure 
(n = 2), and death due to heart rupture (n = 1). 
 
4. Discussion 
 
 The main finding of this prospective, multicenter, randomized study was that RIPC 
induced by intermittent upper-arm ischemia before emergency PCI dramatically reduced the 
incidence of CI-AKI in patients with STEMI. Multivariate logistic analysis revealed that this 
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protective effect was independent of other risk factors. Additionally, the reduction in CI-AKI was 
accompanied by a reduction in infarct size and dysrhythmic events within 24 hours after PCI. 
 To date, there is no effective prophylactic drug regimen to prevent CI-AKI. Atrial 
natriuretic peptide, dopamine, fenoldopam, furosemide, mannitol, aminophylline, captopril, and 
calcium-channel blockers have been reported to be ineffective at reducing the incidence of 
CI-AKI [14-17]. The effect of N-acetylcysteine remains controversial. Initial studies showed that 
N-acetylcysteine was effective at preventing CI-AKI [18]; however, subsequent larger trials 
failed to demonstrate any benefit [19, 20]. RIPC has been reported to decrease the incidence of 
myocardial injury during cardiac surgery
 
[9, 21]
 
and PCI [22] and to reduce the incidence of both 
myocardial injury and renal injury during endovascular surgery [23] and surgical repair of 
abdominal aortic aneurysm [24]. Furthermore, a recent study showed that RIPC before PCI 
attenuated CIN in patients undergoing elective coronary angiography [10]. Consistent with these 
results, our study clearly demonstrated a nephroprotective effect of RIPC in STEMI patients who 
underwent PCI. RIPC can be applied easily and without safety concerns if it is performed 
appropriately. Given the results of the present study, RIPC before PCI may be considered for the 
prevention of CI-AKI in patients with STEMI. 
 CI-AKI is a frequent and serious complication after coronary angiography and is an 
independent predictor of mortality in patients with coronary artery disease [4, 5]. Mehran et al. 
[13] developed a system of risk stratification to predict the risk of CIN in patients undergoing 
elective coronary angiography. This risk-stratification score includes eight clinical and procedural 
variables and is divided into four risk classes: low risk (score < 5), moderate risk (6–10), high 
risk (11–15), and very high risk (≥16). In this study, the mean score was 7 in both groups, 
indicating that our study population was at moderate risk of developing CI-AKI. Indeed, the 
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CI-AKI incidence of 35% in the control group is within the reported range [25] and corresponds 
to the incidence predicted by Mehran et al. [13]. 
 In this study, the risk of CI-AKI in patients with STEMI was associated with RIPC and 
left anterior descending artery as the culprit artery. The number of the Mehran risk-score points 
assigned for a hemodynamic status such as hypotension, use of the intra-aortic balloon pump, or 
chronic heart failure was higher than the number of points assigned for level of renal function and 
volume of contrast medium in patients undergoing elective coronary angiography. Our results 
indicate that the risk of CI-AKI in STEMI patients undergoing emergency PCI may be associated 
with hemodynamic status. 
 Despite its potential clinical significance, the precise pathophysiological mechanisms of 
the action of RIPC on CI-AKI have not yet been elucidated. The pathogenesis of CI-AKI is 
multifactorial and involves vascular, hemodynamic, and tubular factors. The most common 
theory of pathophysiology of CI-AKI is the induction of renal ischemic injury, possibly caused by 
iodinated contrast medium-induced reduction in renal blood flow and oxygen 
free-radical-mediated direct tubular toxicity [22]. Beneficial effects of RIPC on CI-AKI could be 
associated with effects on mitochondria [26], circulating inflammatory cells [27], transcriptional 
upregulation of protective pathways [28, 29], and neural pathways [7].  
 There are several limitations to this study. This pilot investigation of the beneficial 
effects of RIPC on renal function had a limited number of subjects. Although we sought to 
prevent any bias by blinding the patients and the data-analysis team, the study design cannot 
prevent all potential bias. The calculation of sample size was based on inaccurate assumptions 
because of the pilot nature of the study. Additionally, although CI-AKI is a valid surrogate maker 
of renal damage and has been described extensively in the literature, it is not a clinical endpoint. 
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The trends toward a lower incidence of ventricular arrhythmia within 24 hours after PCI and 
fewer MACCE in the 30 days after PCI observed in the RIPC group are important, but do not 
equate to a primary outcome measure, for which a study with greater statistical power is needed. 
 In conclusion, we have demonstrated that RIPC before PCI in patients with STEMI 
reduced the incidence of CI-AKI. Moreover, the reduction of CI-AKI translated to a trend toward 
better clinical outcomes in the 30-day follow-up period. The described RIPC protocol is simple 
and well tolerated and thus may be a feasible and attractive therapeutic option. Nonetheless, a 
large-scale clinical trial is needed to confirm the efficacy of this approach. 
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Figure legends 
 
Fig. 1. Study flow diagram. 
 
Fig. 2. Incidence of (A) CI-AKI and (B) maximum decrease in eGFR 48–72 hours after injection 
of contrast medium in the RIPC and control groups. (C) Serial changes in serum creatinine in the 
RIPC and control groups. CI-AKI, contrast-induced acute kidney injury; eGFR, estimated 
glomerular filtration rate; RIPC, remote ischemic preconditioning. Data expressed as 
mean ± standard deviation.  
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Table 1 
Baseline clinical characteristics. 
 All patients (n=125) Patients who met criteria (n=94) 
 
Control group 
(n = 62) 
RIPC group 
(n = 63) 
p value 
Control 
group 
(n = 47) 
RIPC 
group 
(n = 47) 
p value 
Age, years 68 ± 14 67 ± 12 0.70 67 ± 15 67 ± 12 0.90 
Male, n (%)  43 (69) 46 (73) 0.75 36 (76) 34 (76) 1.00 
Hypertension, n (%)  35 (56) 37 (58) 0.97 31 (65) 29 (61) 0.67 
Dyslipidemia, n (%) 29 (46) 28 (44) 0.65 25 (53) 24 (51) 0.84 
Diabetes, n (%) 22 (35) 18 (28) 0.33 17 (37) 14 (31) 0.56 
Hemoglobin index, mg/dl 13.4 ± 2.0 13.5 ± 2.0 0.95 13.7 ± 2.0 13.7 ± 1.8 0.92 
Current smoker, n (%) 26 (41) 33 (52) 0.31 24 (51) 28 (59) 0.42 
Previous MI, n (%) 3 (4) 7 (11) 0.21 3 (6) 7 (14) 0.15 
Pre-MI angina pectoris, n (%) 31 (50) 30 (47) 0.99 28 (59) 24 (51) 0.35 
Killip grade 1.4 ± 0.9 1.5 ± 0.8 0.64 1.3 ± 0.6 1.4 ± 0.7 0.44 
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Systolic blood pressure, mmHg 131 ± 27 129 ± 29 0.68 136 ± 25 133 ± 30 0.59 
Serum creatinine at admission, 
mg/dl 
0.91 ± 0.44 1.0 ± 1.15 0.55 0.87 ± 0.44 
0.82 ± 
0.21 
0.42 
eGFR at admission, 
ml/min/1.73m
2
 
75 ± 32 71 ± 25 0.55 79 ± 33 73 ± 20 0.22 
Mehran CIN risk score 7.9 ± 6.0 8.2 ± 6.0 0.80 7.4 ± 5.6 7.8 ± 6.0 0.73 
Pre-MI medications       
    Antiplatelets,  
    n (%) 
8 (12) 6 (9) 0.48 8 (17) 3 (6) 0.13 
    β-blockers, n (%) 2 (3) 3 (4) 0.70 2 (4) 3 (6) 0.65 
    Calcium channel 
    blockers, n (%) 
10 (16) 18 (27) 0.12 9 (19) 13 (27) 0.32 
    ACEI/ARB, n (%) 14 (22) 16 (25) 0.83 13 (27) 13 (27) 1.00 
    Statins, n (%) 9 (14) 10 (15) 0.92 7 (14) 8 (17) 0.78 
 
Values expressed as mean ± SD or n (%).  
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II-receptor blocker; CIN = contrast medium-induced 
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nephropathy; eGFR = estimated glomerular filtration rate; MI = myocardial infarction; RIPC = remote ischemic preconditioning.
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Table 2 
Procedural results. 
 All patients (n=125) Patients who met criteria (n=94) 
 
Control group 
(n = 62) 
RIPC group 
(n = 63) 
p 
value 
Control group 
(n = 47) 
RIPC group 
(n = 47) 
p 
value 
Infarct-related coronary artery       
    LAD artery 26 (41) 23 (36) 0.48 21 (44) 19 (40) 0.67 
    Non-LAD artery 36 (59) 40 (64) 0.48 26 (56) 28 (60) 0.67 
TIMI flow grade at admission 0.7 ± 1.0 0.8 ± 1.1 0.70 0.5 ± 0.8 0.5 ± 1.0 0.81 
Symptom-to-balloon time, min 615 ± 925 638 ± 1072 0.90 360 ± 274 326 ± 278 0.41 
Door-to-balloon time, min 106 ± 39 115 ± 72 0.45 104 ± 35 115 ± 74 0.80 
Stenting of culprit lesion by PCI 53 (85) 49 (77) 0.14 46 (97) 44 (93) 0.32 
IABP support 15 (24) 13 (20) 0.79 10 (21) 9 (19) 0.79 
TIMI flow grade after procedure 2.7 ± 0.4 2.7 ± 0.4 0.73 2.6 ± 0.5 2.7 ± 0.4 0.31 
Collected TIMI flow counts after 
procedure, counts 
20 ± 11 23 ± 26 0.53 22 ± 12 20 ± 14 0.54 
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Values expressed as mean ± SD or n (%).  
IABP = intra-aortic balloon pump; LAD = left anterior descending; PCI = percutaneous coronary intervention; RIPC = remote 
ischemic preconditioning; TIMI = thrombolysis in myocardial infarction. 
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Table 3. Concomitant medications between completion of RIPC and primary end point. 
 
 
 Control group 
(n=47) 
RIPC group 
(n=47) 
p value 
Furosemide (intravenous) 5 (10) 3 (6) 0.48 
Furosemide (oral) 3 (6) 5 (10) 0.48 
Spironolactone (oral) 3 (6) 1 (2) 0.32 
Carperitide (intravenous) 4 (8) 3 (6) 0.70 
Isosorbide (oral) 2 (4) 3 (6) 0.65 
Nicorandil (oral) 30 (63) 26 (55) 0.41 
Dopamine (intravenous) 4 (8) 4 (8) 1.00 
Dobutamine (intravenous) 1 (2) 1 (2) 1.00 
Values are n (%).  
RIPC = remote ischemic preconditioning. 
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Table 4 
Results of logistic regression analyses for CI-AKI. 
 Univariate analysis Multivariate analysis 
 Odds ratio 95% CI p value Odds ratio 95% CI p value 
Age >68 years 4.49 1.49–13.5 0.007 3.38 0.88-12.88 0.07 
Male 0.31 0.11–0.90 0.03 0.55 0.13-2.30 0.41 
Hypertension 1.69 0.59–4.85 0.32    
Dyslipidemia 0.89 0.34–2.32 0.81    
Diabetes 0.93 0.33–2.59 0.89    
Current smoker 0.28 0.10–0.77 0.01 0.73 0.19–2.79 0.64 
Previous MI 0.33 0.04–2.78 0.31    
Systolic blood pressure 
>136 mmHg 
2.06 0.77–5.53 0.14    
Hemoglobin <13.8 mg/dl  1.70 0.64–4.49 0.27    
Killip grade >1 0.91 0.31–2.64 0.86    
TIMI flow grade at 0.99 0.35–2.77 0.99    
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admission >0 
Pre-MI angina pectoris 2.66 0.93–7.58 0.06    
LAD as ‘culprit artery’ 4.02 1.45–11.17 0.007 3.50 1.08–11.31 0.03 
Bare metal stent use 0.97 0.33–2.84 0.96    
Symptom-to-balloon time 
>238 minutes 
2.67 0.97–7.35 0.05    
TIMI flow grade after 
procedure <3 
1.23 0.43–3.41 0.71    
Collected TIMI flow counts 
after procedure >18 counts 
1.68 0.64–4.39 0.29    
CK >2760 IU/L 1.70 0.64–4.49 0.27    
CK-MB >222 IU/L  2.18 0.81–5.85 0.11    
LVEF <55%  0.84 0.31–2.27 0.74    
IABP 1.21 0.38–3.86 0.81    
VF or sustained VT within 
24 hours after PCI 
0.90 0.17-4.86 0.91    
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50% or more ST-segment 
resolution 
0.35 0.13-0.96 0.04 0.48 0.15-1.54 0.22 
Mehran CIN risk score >6 1.25 0.48–3.25 0.64    
Creatinine >0.77 mg/dl * 0.54 0.20–1.44 0.22    
eGFR <74 ml/min/1.73m
2
 1.95 0.73–5.23 0.18    
Contrast medium >175 ml 1.26 0.48–3.30 0.62    
RIPC 0.21 0.07–0.63 0.006 0.18 0.05–0.64 0.008 
Continuous variables were transformed to binary data according to median value. CI-AKI = contrast medium-induced acute kidney 
injury; CIN = contrast medium-induced nephropathy; CK = creatine kinase; IABP = intra-aortic balloon pump; LAD = left anterior 
descending; LVEF = left ventricular ejection fraction; MB = myocardial band; MI = myocardial infarction; RIPC = remote ischemic 
preconditioning; TIMI = thrombolysis in myocardial infarction; VF = ventricular fibrillation; VT = ventricular tachycardia. 
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Table 5 
Secondary outcomes. 
 
Control group 
(n = 47) 
RIPC group 
(n = 47) 
p value 
Peak CK, IU/L 3653 ± 2894 2648 ± 1929 0.04 
Peak CK-MB, IU/L 303 ± 267 238 ± 159 0.15 
VF or sustained VT within 24 hours after PCI 7 1 0.02 
% ST-segment resolution, % 51 ± 33 62 ± 28 0.09 
50% or more ST-segment resolution 29 (61) 35 (74) 0.18 
Left ventricular ejection fraction, % 54 ± 13 54 ± 12 0.84 
MACCE    
    Total 7 (14) 2 (4) 0.07 
    Cardiac death 3 0  
    Heart failure 3 1  
    Ventricular perforation 1 0  
    Stroke 0 1  
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Values expressed as mean ± SD or n (%).  
CK = creatine kinase; LVEF = left ventricular ejection fraction; MACCE = major adverse cardiac and cerebral events; 
MB = myocardial band; RIPC = remote ischemic preconditioning; VF = ventricular fibrillation; VT = ventricular tachycardia. 
 
 
 
